An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of RM-493, a MC4R Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation

Trial Profile

An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of RM-493, a MC4R Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 09 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top